Applied Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Applied Therapeutics generated cash of -$55,173,000, which is more than the previous year. Cash used in financing activities reached the amount of $74,542,000 last year. Net change in cash is therefore $33,241,000.
Cash Flow
| 2017 | -3.19M | 0 | 6.47M |
|---|---|---|---|
| 2018 | -11.18M | 0 | 26.65M |
| 2019 | -36.30M | -20.00M | 56.41M |
| 2020 | -78.20M | -19.46M | 136.29M |
| 2021 | -90.72M | 12.43M | 74.71M |
| 2022 | -78.09M | 13.17M | 27.69M |
| 2023 | -55.17M | 13.87M | 74.54M |
APLT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 16.65M | 53.88M | 57.46M | 18.85M | 18.74M | 3.27M | 2K |
Operating activities | |||||||
Net income | -119.76M | -82.50M | -105.58M | -93.96M | -45.51M | -16.52M | -4.28M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 354K | 443K | 415K | 380K | 23K | 0 | 0 |
Stock-based compensation expense | 7.36M | 9.60M | 11.17M | 8.02M | 6.17M | 0 | 32K |
| Deferred income tax benefit | 7.36M | 9.60M | 11.17M | 8.02M | 6.17M | 0 | 32K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.79M | -4.92M | 8.82M | -8.04M | 5.75M | 2.30M | 499K |
Cash generated by operating activities | -55.17M | -78.09M | -90.72M | -78.20M | -36.30M | -11.18M | -3.19M |
Investing activities | |||||||
Purchases Of Investments | 0 | -64.21M | -121.58M | -134.65M | -20.00M | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 13.87M | 13.17M | 12.43M | -19.46M | -20.00M | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 64.51M | 27.81M | 75.00M | 135.71M | 55.71M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.85M | -3.27M | -4.71M | -2.14M | 0 | 0 | 0 |
Cash used in financing activities | 74.54M | 27.69M | 74.71M | 136.29M | 56.41M | 26.65M | 6.47M |
Net Change In Cash | 33.24M | -37.23M | -3.57M | 38.61M | 102K | 15.47M | 3.27M |
Cash at end of period | 49.89M | 16.65M | 53.88M | 57.46M | 18.85M | 18.74M | 3.27M |
| Data source | Data source | Data source | Data source | Data source |